Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol

Hsien Yuan Lane, Hsin Nan Lin, Oliver Yoa Pu Hu, Chiao Chicy Chen, Michael W. Jann, Wen Ho Chang

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The studies of relationships between blood levels of reduced haloperidol HL (RH) and clinical efficacy in haloperidol (HL)-treated patients have yielded variable results. On the other hand, the contribution of RH upon HL's extrapyramidal side effects (EPS) had been suggested in animal models as well as in preliminary clinical studies with limited subjects. This study explored the relationships between blood drug levels and clinical effects and EPS of HL in 48 Chinese acutely exacerbated schizophrenic inpatients. After a single-blind placebo period of one week, the patients were treated with a fixed dose of 10 mg of HL for two weeks. Steady-state levels of HL and RH in plasma (n = 48) and in red blood cells (RBC) (n = 37) were measured by high performance liquid chromatography. The mean RH/HL ratio in RBC in the Chinese (0.55) is lower than that in non-Chinese patients as reported in the literature (> 2), so is the RH/HL ratios in plasma. No significant relationship emerged between percent improvement in BPRS total score and any of drug indices (HL, RH, sum of two compounds [HL + RH], and RH/HL ratio) in plasma and in RBC. Furthermore, the responders did not differ significantly from the nonresponders in each drug index. Plasma RH levels were significantly higher in 30 patients experiencing EPS compared with the other 18 patients (mean 2.14 ± 1.71 [S.D.] ng/ml vs. 1.38 ± 0.37 ng/ml, p < 0.05). No significant differences in other drug indices were noted between subjects with or without EPS.

Original languageEnglish
Pages (from-to)299-311
Number of pages13
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume21
Issue number2
DOIs
Publication statusPublished - Feb 1 1997
Externally publishedYes

Fingerprint

Haloperidol
Erythrocytes
Pharmaceutical Preparations
4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol
Inpatients
Animal Models
High Pressure Liquid Chromatography
Placebos

Keywords

  • haloperidol
  • plasma concentration
  • red blood cell concentration
  • reduced haloperidol

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry

Cite this

Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol. / Lane, Hsien Yuan; Lin, Hsin Nan; Hu, Oliver Yoa Pu; Chen, Chiao Chicy; Jann, Michael W.; Chang, Wen Ho.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 21, No. 2, 01.02.1997, p. 299-311.

Research output: Contribution to journalArticle

Lane, Hsien Yuan ; Lin, Hsin Nan ; Hu, Oliver Yoa Pu ; Chen, Chiao Chicy ; Jann, Michael W. ; Chang, Wen Ho. / Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 1997 ; Vol. 21, No. 2. pp. 299-311.
@article{f7f71b6115934c4fa8f658c60cb2bd4f,
title = "Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol",
abstract = "The studies of relationships between blood levels of reduced haloperidol HL (RH) and clinical efficacy in haloperidol (HL)-treated patients have yielded variable results. On the other hand, the contribution of RH upon HL's extrapyramidal side effects (EPS) had been suggested in animal models as well as in preliminary clinical studies with limited subjects. This study explored the relationships between blood drug levels and clinical effects and EPS of HL in 48 Chinese acutely exacerbated schizophrenic inpatients. After a single-blind placebo period of one week, the patients were treated with a fixed dose of 10 mg of HL for two weeks. Steady-state levels of HL and RH in plasma (n = 48) and in red blood cells (RBC) (n = 37) were measured by high performance liquid chromatography. The mean RH/HL ratio in RBC in the Chinese (0.55) is lower than that in non-Chinese patients as reported in the literature (> 2), so is the RH/HL ratios in plasma. No significant relationship emerged between percent improvement in BPRS total score and any of drug indices (HL, RH, sum of two compounds [HL + RH], and RH/HL ratio) in plasma and in RBC. Furthermore, the responders did not differ significantly from the nonresponders in each drug index. Plasma RH levels were significantly higher in 30 patients experiencing EPS compared with the other 18 patients (mean 2.14 ± 1.71 [S.D.] ng/ml vs. 1.38 ± 0.37 ng/ml, p < 0.05). No significant differences in other drug indices were noted between subjects with or without EPS.",
keywords = "haloperidol, plasma concentration, red blood cell concentration, reduced haloperidol",
author = "Lane, {Hsien Yuan} and Lin, {Hsin Nan} and Hu, {Oliver Yoa Pu} and Chen, {Chiao Chicy} and Jann, {Michael W.} and Chang, {Wen Ho}",
year = "1997",
month = "2",
day = "1",
doi = "10.1016/S0278-5846(97)00007-9",
language = "English",
volume = "21",
pages = "299--311",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol

AU - Lane, Hsien Yuan

AU - Lin, Hsin Nan

AU - Hu, Oliver Yoa Pu

AU - Chen, Chiao Chicy

AU - Jann, Michael W.

AU - Chang, Wen Ho

PY - 1997/2/1

Y1 - 1997/2/1

N2 - The studies of relationships between blood levels of reduced haloperidol HL (RH) and clinical efficacy in haloperidol (HL)-treated patients have yielded variable results. On the other hand, the contribution of RH upon HL's extrapyramidal side effects (EPS) had been suggested in animal models as well as in preliminary clinical studies with limited subjects. This study explored the relationships between blood drug levels and clinical effects and EPS of HL in 48 Chinese acutely exacerbated schizophrenic inpatients. After a single-blind placebo period of one week, the patients were treated with a fixed dose of 10 mg of HL for two weeks. Steady-state levels of HL and RH in plasma (n = 48) and in red blood cells (RBC) (n = 37) were measured by high performance liquid chromatography. The mean RH/HL ratio in RBC in the Chinese (0.55) is lower than that in non-Chinese patients as reported in the literature (> 2), so is the RH/HL ratios in plasma. No significant relationship emerged between percent improvement in BPRS total score and any of drug indices (HL, RH, sum of two compounds [HL + RH], and RH/HL ratio) in plasma and in RBC. Furthermore, the responders did not differ significantly from the nonresponders in each drug index. Plasma RH levels were significantly higher in 30 patients experiencing EPS compared with the other 18 patients (mean 2.14 ± 1.71 [S.D.] ng/ml vs. 1.38 ± 0.37 ng/ml, p < 0.05). No significant differences in other drug indices were noted between subjects with or without EPS.

AB - The studies of relationships between blood levels of reduced haloperidol HL (RH) and clinical efficacy in haloperidol (HL)-treated patients have yielded variable results. On the other hand, the contribution of RH upon HL's extrapyramidal side effects (EPS) had been suggested in animal models as well as in preliminary clinical studies with limited subjects. This study explored the relationships between blood drug levels and clinical effects and EPS of HL in 48 Chinese acutely exacerbated schizophrenic inpatients. After a single-blind placebo period of one week, the patients were treated with a fixed dose of 10 mg of HL for two weeks. Steady-state levels of HL and RH in plasma (n = 48) and in red blood cells (RBC) (n = 37) were measured by high performance liquid chromatography. The mean RH/HL ratio in RBC in the Chinese (0.55) is lower than that in non-Chinese patients as reported in the literature (> 2), so is the RH/HL ratios in plasma. No significant relationship emerged between percent improvement in BPRS total score and any of drug indices (HL, RH, sum of two compounds [HL + RH], and RH/HL ratio) in plasma and in RBC. Furthermore, the responders did not differ significantly from the nonresponders in each drug index. Plasma RH levels were significantly higher in 30 patients experiencing EPS compared with the other 18 patients (mean 2.14 ± 1.71 [S.D.] ng/ml vs. 1.38 ± 0.37 ng/ml, p < 0.05). No significant differences in other drug indices were noted between subjects with or without EPS.

KW - haloperidol

KW - plasma concentration

KW - red blood cell concentration

KW - reduced haloperidol

UR - http://www.scopus.com/inward/record.url?scp=0030993544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030993544&partnerID=8YFLogxK

U2 - 10.1016/S0278-5846(97)00007-9

DO - 10.1016/S0278-5846(97)00007-9

M3 - Article

C2 - 9061775

AN - SCOPUS:0030993544

VL - 21

SP - 299

EP - 311

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 2

ER -